Comparative Pharmacology
Head-to-head clinical analysis: CEFTAROLINE FOSAMIL versus ROCEPHIN KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTAROLINE FOSAMIL versus ROCEPHIN KIT.
CEFTAROLINE FOSAMIL vs ROCEPHIN KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftaroline fosamil is a prodrug that is converted to the active metabolite ceftaroline. Ceftaroline inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), including PBP2a in MRSA and PBP2x in Streptococcus pneumoniae, thereby preventing cross-linking of peptidoglycan.
Ceftriaxone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis and death.
600 mg IV every 12 hours infused over 1 hour
Adult: 1-2 g IV or IM every 24 hours. Maximum 4 g/day for severe infections.
None Documented
None Documented
Terminal elimination half-life is approximately 2.6 hours in patients with normal renal function. This supports twice-daily dosing in most infections.
Terminal half-life 6-9 hours in healthy adults; prolonged to 12-15 hours in elderly and up to 30 hours in severe renal impairment (CrCl <10 mL/min).
Renal excretion of unchanged ceftaroline accounts for approximately 88% of the administered dose. Biliary/fecal elimination is minimal (<6%).
Renal (33-67% unchanged), biliary (40-50% as active drug and metabolites), fecal (minor).
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic